Yujiro Nakano

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study

Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara et al. · Cardiovascular Diabetology · 2017 · 167 citations · Full text

Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study

Tatsuya Fukuda, Ryotaro Bouchi, Masahiro Terashima et al. · Diabetes Therapy · 2017 · 116 citations · Full text

Indirect measure of visceral adiposity ‘A Body Shape Index’ (ABSI) is associated with arterial stiffness in patients with type 2 diabetes

Ryotaro Bouchi, M Asakawa, Norihiko Ohara et al. · BMJ Open Diabetes Research & Care · 2016 · 113 citations · Full text

Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial

Ryotaro Bouchi, Yujiro Nakano, Tatsuya Fukuda et al. · Endocrine Journal · 2016 · 108 citations · Full text

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial

Yumie Takeshita, Masao Honda, Kenichi Harada et al. · Diabetes Care · 2022 · 105 citations · Full text